|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-2-24
|
|
pubmed:abstractText |
Chronic L-3,4-dihydroxyphenylalanine (L-DOPA) treatment of Parkinson's disease (PD) leads to debilitating involuntary movements, termed L-DOPA-induced dyskinesia. Striatofugal medium spiny neurons (MSN) lose their dendritic spines and cortico-striatal glutamatergic synapses in PD and in experimental models of DA depletion. This loss of connectivity is triggered by a dysregulation of intraspine Cav1.3 L-type Ca2+ channels. Here we address the possible implication of DA denervation-induced spine pruning in the development of L-DOPA-induced dyskinesia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channels, L-Type,
http://linkedlifedata.com/resource/pubmed/chemical/Enkephalins,
http://linkedlifedata.com/resource/pubmed/chemical/Isradipine,
http://linkedlifedata.com/resource/pubmed/chemical/Levodopa,
http://linkedlifedata.com/resource/pubmed/chemical/Nimodipine,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidopamine,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Precursors,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Sympatholytics,
http://linkedlifedata.com/resource/pubmed/chemical/preproenkephalin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1873-2402
|
|
pubmed:author |
pubmed-author:AubertIncarnationI,
pubmed-author:BerthetAmandineA,
pubmed-author:BezardErwanE,
pubmed-author:BlochBertrandB,
pubmed-author:CenciM AngelaMA,
pubmed-author:DoudnikoffEvelyneE,
pubmed-author:HengererBastianB,
pubmed-author:IttrichCarinaC,
pubmed-author:RylanderDaniellaD,
pubmed-author:SchusterStefanS,
pubmed-author:SurmeierD JamesDJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
518-26
|
|
pubmed:meshHeading |
pubmed-meshheading:18947822-Animals,
pubmed-meshheading:18947822-Calcium Channel Blockers,
pubmed-meshheading:18947822-Calcium Channels, L-Type,
pubmed-meshheading:18947822-Cerebrum,
pubmed-meshheading:18947822-Dendritic Spines,
pubmed-meshheading:18947822-Disease Models, Animal,
pubmed-meshheading:18947822-Dose-Response Relationship, Drug,
pubmed-meshheading:18947822-Dyskinesia, Drug-Induced,
pubmed-meshheading:18947822-Enkephalins,
pubmed-meshheading:18947822-Isradipine,
pubmed-meshheading:18947822-Levodopa,
pubmed-meshheading:18947822-Male,
pubmed-meshheading:18947822-Motor Activity,
pubmed-meshheading:18947822-Nimodipine,
pubmed-meshheading:18947822-Oxidopamine,
pubmed-meshheading:18947822-Protein Precursors,
pubmed-meshheading:18947822-RNA, Messenger,
pubmed-meshheading:18947822-Rats,
pubmed-meshheading:18947822-Rats, Wistar,
pubmed-meshheading:18947822-Sympatholytics
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
|
|
pubmed:affiliation |
Boehringer Ingelheim Pharma GmbH & Company KG, Biberach, Germany.
|
|
pubmed:publicationType |
Journal Article
|
